AroCell AB (publ) announced the signing of an additional agreement with ZECEN Biotech Co., Ltd. for the development of the company's third tumor marker product, TK 210 ELISA, which will be included on ZECEN Biotech's automated platforms. This partnership marks a major milestone for AroCell as the company continue to expand product offerings and improve cancer diagnostics. AroCell has been collaborating with ZECEN Biotech since 2019 for the development of TPS CLIA on ZECEN Biotech and Fosun's automated CLIA platforms, which are now available on the Chinese market. There is also an ongoing collaboration for the automatization of UBC that started earlier this year.

The addition of a third marker, TK1, to automated platforms is consistent with AroCell's strategy to make its biomarkers available to a larger patient population and further strengthen AroCell's presence in the Chinese market.